Oriahnn — Medica

Initial criteria

• Patient age ≥ 18 years
• Patient is premenopausal
• Patient is experiencing heavy menstrual bleeding associated with uterine fibroids
• Uterine fibroids have been confirmed by pelvic ultrasound (including transvaginal ultrasonography or sonohysterography), hysteroscopy, or magnetic resonance imaging
• Patient has tried at least one other therapy for the medical management of heavy menstrual bleeding (e.g., combination estrogen-progestin contraceptives [oral tablets, vaginal ring, transdermal patch], levonorgestrel-releasing intrauterine systems [e.g., Mirena, Liletta], oral progesterone [e.g., medroxyprogesterone acetate], depo-medroxyprogesterone injection, tranexamic acid tablets)
• Patient has not previously received a continuous regimen of 24 months or longer of therapy with Oriahnn or Myfembree
• Medication is prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner specializing in women’s health

Approval duration

up to 24 months (reduced accordingly if some therapy already completed)